McKechnie Duncan 4

What Happened
McKechnie Duncan, EVP and Chief Commercial Officer of Vertex Pharmaceuticals (VRTX), sold a total of 5,783 shares between Feb 24–25, 2026 for aggregate proceeds of about $2,817,866. The breakdown: 873 shares on 2026-02-24 at $485.11 ($423,501) reported as a payment of exercise price/tax liability (code F), and two open-market sales on 2026-02-25 of 2,500 shares at $486.35 ($1,215,875) and 2,410 shares at $489.00 ($1,178,490). These were dispositions (sales), not purchases.

Key Details

• Dates & prices: 02/24/2026 — 873 @ $485.11 (F); 02/25/2026 — 2,500 @ $486.35 (S); 02/25/2026 — 2,410 @ $489.00 (S).
• Total sold: 5,783 shares for approximately $2,817,866.
• Post-transaction holdings: Not specified in the provided filing excerpt.
• Footnote: Trades were made pursuant to a company‑approved Rule 10b5‑1 trading plan entered 11/25/2025 (per filing).
• Transaction codes: F = payment of exercise price/tax withholding (sell-to-cover); S = open-market sale.
• Timeliness: Form 4 filed 2026-02-26 for transactions on 02/24–02/25; no late filing noted in the supplied data.

Context
The F-coded disposition indicates shares were used to satisfy an exercise or tax obligation (a common "sell-to-cover"). The filing also states the trades were executed under a prearranged 10b5‑1 plan, which typically schedules transactions in advance and is not a direct, immediate signal of the insider’s view on the stock. Sales are routine and do not necessarily reflect company prospects; purchases generally carry more weight for interpreting insider sentiment.